VITEK(R) 2 GP, REF 21342, IVD, UDI 03573026131920, bioMerieux, Inc. VITEK(R) 2 is an automated system consisting of instruments, software and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The VITEK® 2 utilizes growth based biochemical patterns to determine identification. The VITEK® 2 provides minimal inhibitory concentration (MIC) results for most organism/drug combinations as well as a category interpretation (S, I, or R) consistent with accepted criteria
Published September 27, 2017 · Recall initiated: August 25, 2017
Summary
FDA records medical device Class II recall Z-3134-2017, published September 27, 2017 and initiated August 25, 2017. Recalling firm: Biomerieux Inc; Status: Terminated; Reported quantity: 11,703 cartons; Lot: Lot Number 2420240403, Exp. 24-JUL-18, 2420303403, Exp 24-SEP-2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Customer reports have indicated occurrences of atypical negative O129R reactions for Enterococcus casseliflavus ATCC(R) 700327(TM) in association with VITEK(R) 2 GP ID Lot 2420240403 and 2420303403, causing failure of the Quality Control (QC) testing for the VITEK(R) 2 GP ID card. The expected O129R reaction for ATCC® 700327(TM) strain is positive.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Biomerieux Inc
- Distributor
- US and Angola, Argentina, Austria, Belarus, Belgium, Burkina Faso, Cameroon, Canada, China, Congo, Croatia, Egypt, France, Germany, Greece, Guam, Hungary, Israel, Italy, Latvia, Luxembourg, Macedonia, Mali, Mexico, Morocco, Netherlands, Nicaragua, Oman, Panama, Poland, Saudi Arabia, Serbia, South Africa, South Korea, Spain, Swaziland, Switzerland, Tunisia, Turkey, Turkmenistan, United Arab Emirates, United Kingdom
- Lot
- Lot Number 2420240403, Exp. 24-JUL-18, 2420303403, Exp 24-SEP-2018
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAVITEK 2 AST-N461 TEST KIT, GRAM NEGATIVE SUSCEPTIBILITY TESTING - AUTOMATED, Reference Number 424811September 30, 2026
- FDAVITEK 2 AST-N447 TEST KIT Product reference 424620July 15, 2026
- FDAVITEK 2 Gram-negative Susceptibility Cards Containing o Polymyxin B (pb02n) o Ceftazidime/avibactam (cza02n) oFebruary 11, 2026
- FDAVITEK 2 - AST Test kits (in vitro diagnostic test cards for antimicrobial susceptibility): a) AST-N334, REFMay 1, 2024
- FDALaxmi Rusks, 10.58 OZ (300 gram) bags; UPC Code: 7 23246 26482 0September 27, 2017
- FDAAQUIOS CL Flow Cytometer System The AQUIOS CL Flow Cytometer is intended for use as an in vitro diagnosticSeptember 27, 2017
Questions about this recall
Was VITEK(R) 2 GP, REF 21342, IVD, UDI 03573026131920, bioMerieux, Inc. VITEK(R) 2 is an automated system consisting of instruments, software and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The VITEK® 2 utilizes growth based biochemical patterns to determine identification. The VITEK® 2 provides minimal inhibitory concentration (MIC) results for most organism/drug combinations as well as a category interpretation (S, I, or R) consistent with accepted criteria recalled?
Yes. FDA published recall Z-3134-2017 on September 27, 2017. Reported hazard: Customer reports have indicated occurrences of atypical negative O129R reactions for Enterococcus casseliflavus ATCC(R) 700327(TM) in association with VITEK(R) 2 GP ID Lot 2420240403 and 2420303403, causing failure of the Quality Control (QC) testing for the VITEK(R) 2 GP ID card. The expected O129R reaction for ATCC® 700327(TM) strain is positive.
What should I do if I have this product?
Voluntary: Firm initiated · Letter